Regional Genetic Heterogeneity Among Patients with Pyruvate Kinase Deficiency

• Published in: Blood Vol. 142; no. Supplement 1; p. 5203
• Main Authors: Bianchi, Paola, Fermo, Elisa, Kuo, Kevin H.M., Pospíšilová, Dagmar, Glenthoej, Andreas, Lander, Carl, Van Beers, Eduard J., Glader, Bertil, Vives Corrons, Joan-Lluis, Eber, Stefan W, Yan, Yan, McGee, Bryan, Ford, Janet H, Yilmaz, Saliha, Grace, Rachael F.
• Format: Journal Article
• Language: English
• Published: Elsevier Inc 02.11.2023
• ISSN: 0006-4971; 1528-0020
• DOI: 10.1182/blood-2023-181834

Background: Pyruvate kinase (PK) deficiency is a rare, congenital hemolytic anemia caused by homozygous or compound heterozygous mutations in the PKLR gene, with a prevalence of 3.2-8.5 individuals per million in Western populations. Over 350 pathogenic variants in the PKLR gene have been reported, with the majority being missense substitutions. Although their frequency differs across regions and populations, the geographic distribution of PKLR variants has not yet been fully investigated. Aim: To evaluate the PKLR genotype distribution by region among patients (pts) with PK deficiency in the merged real-world database of the Peak Registry (NCT03481738) and PK Deficiency Natural History Study (NHS; NCT02053480). Methods: The NHS was a global, longitudinal, observational study that enrolled pts with PK deficiency from 2014-2017 (study completed May 2020). The Peak Registry is an ongoing global registry which was initiated in 2018 to build on the NHS with expanded pt recruitment and geographic reach, broader data collection, and longer pt follow-up. Comparable data from these two studies were integrated to form a merged database providing enlarged sample size and prolonged follow-up from pts who participated in both studies. This analysis included pts with available genotype data from the NHS and Peak Registry, including those who were siblings; a large Amish cohort of pts carrying the homozygous p.R479H variant was excluded to avoid reporting bias. Genotype classifications were aligned between the two studies. Data were extracted from the merged database of NHS and Peak (data cutoff date: 13May2022) and summarized descriptively by region. Regions were defined as: Northern (N) Europe (Denmark, Ireland, Netherlands, UK); Central (C) Europe (Czech Republic, Germany, Switzerland); Southern (S) Europe (France, Italy, Spain, Portugal); Asia (S Korea, Thailand, Turkey); N America (Canada, US). Results: 362 pts were included in the analysis (N Europe, N=59; S Europe, N=62; C Europe, N=51; Asia, N=23; N America, N=167), 97 (27%) of whom were siblings. Most pts (72%) had compound heterozygous PKLR variants (Table). Homozygous mutations were most common among pts from Asia (15/23; 65%) and were least common among pts from S Europe (8/62; 13%). Almost half of pts from N Europe (49%) had a compound heterozygous missense/missense (M/M) genotype, while a similar proportion from S Europe (44%) had a compound heterozygous missense/non-missense (M/NM) genotype. A total of 724 PKLR variants were identified, including 197 unique variants, 26 of which were newly identified. Most were missense mutations (76%), followed by nonsense (10%), splice site (7%), and frameshift (5%) mutations. The majority of mutated alleles in the cohort were single nucleotide variants (90%), followed by small deletions (4%), large deletions (4%), and insertions (2%). The amino acid variant with the highest observed frequency was p.Arg510Gln, both overall (158/724; 22%), and in N Europe (31/118; 26%), C Europe (27/102; 26%), and N America (92/334; 28%), but it was not observed in Asia (0/46; 0%). The second most common variant overall, p.Arg486Trp (67/724; 9%), was the most frequent in S Europe (31/124; 25%). When stratified by genotype, p.Arg510Gln was the most common missense mutation in homozygous pts in each region (40-67%) except in Asia. In Asia, p.Thr157Ala, p.Lys541Asn, and p.Arg194Pro were the most common mutations overall (4/46; 9%), and also the most common missense mutations in homozygous pts (4/28; 14%). One hundred and seventy-four unique variants were observed in compound heterozygotes. In S Europe (27/102; 26%) and Asia (2/10; 20%), p.Arg486Trp was the most frequently observed missense mutation in compound heterozygote pts. Overall and in all regions except for Asia (where it was absent), p.Glu241Ter was the most common non-missense mutation in compound heterozygote pts (32/254; 13%); this was p.Gly540Ter (3/6; 50%) in Asia. Conclusions: This analysis, which used the largest real-world data source for pts with PK deficiency, confirms the genetic heterogeneity of the disease, showing that the mutation frequency in PKLR varies substantially based on geographic distribution and that the identification of novel genetic variants is relatively common in PK deficiency. Bianchi:Agios Pharmaceuticals, Inc.: Other: Scientific advisor. Kuo:Bristol Myers Squibb: Consultancy, Honoraria; Forma Therapeutics: Consultancy; Pfizer: Consultancy; Bioverativ/Sanofi/Sangamo: Membership on an entity's Board of Directors or advisory committees; Novo/Nordisk: Consultancy, Honoraria; Alexion Pharmaceuticals: Consultancy; Agios Pharmaceuticals: Consultancy, Research Funding; Vertex Pharmaceuticals: Consultancy. Glenthoej:Sanofi: Research Funding; Novo Nordisk: Consultancy, Membership on an entity's Board of Directors or advisory committees; Bristol Myers Squibb: Consultancy, Membership on an entity's Board of Directors or advisory committees; bluebird bio: Consultancy, Membership on an entity's Board of Directors or advisory committees; Saniona: Research Funding; Pharmacosmos: Consultancy, Membership on an entity's Board of Directors or advisory committees; Agios: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees. Lander:Agios Pharmaceuticals, Inc.: Membership on an entity's Board of Directors or advisory committees. Van Beers:Pfizer, Inc.: Research Funding; Novartis AG: Research Funding; RR Mechatronics: Research Funding; Agios Pharmaceuticals, Inc. Inc.: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding. Glader:Agios Pharmaceuticals, Inc.: Consultancy, Research Funding. Eber:Agios Pharmaceuticals, Inc.: Membership on an entity's Board of Directors or advisory committees. Yan:Agios Pharmaceuticals, Inc.: Current Employment, Current equity holder in publicly-traded company. McGee:Agios Pharmaceuticals, Inc.: Current Employment, Current equity holder in publicly-traded company. Ford:Agios Pharmaceuticals, Inc.: Current Employment, Current equity holder in publicly-traded company. Yilmaz:Agios Pharmaceuticals, Inc.: Current Employment, Current equity holder in publicly-traded company. Grace:Sobi: Research Funding; Sanofi: Consultancy; Novartis: Research Funding; Agios: Consultancy, Research Funding. [Display omitted]